Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
2(50.0%)
N/A
1(25.0%)
Phase 1
1(25.0%)
4Total
Early Phase 1(2)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06148636Early Phase 1Active Not Recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Role: lead

NCT04614766Phase 1Withdrawn

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Role: lead

NCT03044977Early Phase 1Active Not Recruiting

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Role: lead

NCT01099228Not ApplicableCompleted

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Role: lead

All 4 trials loaded